Examining the anti-inflammatory role of TSLP in the immune system through activation of Regulatory T Cells
Introduction
The immune system plays an important role in maintaining homeostasis, especially at barrier surfaces such as the skin, lungs, and gut. These tissues require regulated immune responses that can defend against threats, prevent hyperinflammation, and heal tissues properly when exposed to pathogens, allergens, and wounds. This balance is maintained through immune cells, cytokines, other signaling molecules, and signal transduction pathways. Regulatory T cells (Tregs) are a subset of CD4⁺ T cells, which detect antigens and signal immune responses, and play an important role in suppressing immune responses to maintain homeostasis. These cells can be activated by certain proteins as a result of signal transduction pathways. For one, Thymic stromal lymphopoietin (TSLP) is a cytokine produced from epithelial cells called keratinocytes, that act as barrier cells found in skin, blood vessels, and organs. Specifically, TSLP shapes immune responses by binding to dendritic cells, macrophages, and T cells, and can be both pro-inflammatory and anti-inflammatory, making it an important target for researchers investigating the immune system. This pro-inflammatory property of TSLP can cause autoimmune or inflammatory disorders, such as ulcerative colitis, atopic dermatitis, or asthma. In contrast, TSLP can also reduce the effects of autoimmune disease through regulating the immune system, such as in the gut or even in the airway. Examining the lesser-known anti-inflammatory traits of TSLP will be helpful to find how it may be used to mitigate autoimmune diseases and decrease harmful inflammation.
Literature Review
Regulatory T cells are produced in the thymus, a gland in the inner chest region, and in some cases, in peripheral tissues, which are tissues not included in the central nervous system. These cells are defined by their expression of the Foxp3 transcription factor, which leads to their differentiation (specification) and suppressive ability. In the skin, they can migrate from circulation into tissue and prefer to localize at hair follicles, where they regulate immune responses. They rely on cytokine protein IL-2 (Interleukin-2) for development and maintenance, but can utilize IL-7 in environments with lower IL-2 availability. They accumulate at injury sites and support regeneration through signals such as epidermal growth factor (EGF). It was found that when the EGF receptor was removed from Tregs, wound healing and replenishment of barrier cells slowed. Regulatory T cells are promoted by the interleukin (cytokine) IL-33, which is released during tissue damage. IL-33 binds to the ST2 receptor, which is highly expressed on Tregs in barrier tissues. This signaling causes Treg differentiation, stability, and proliferation, and maintains Foxp3 expression through activating transcription factors such as GATA3. IL-23, a pro-inflammatory cytokine, disrupts the IL-33 pathway by reducing ST2 and GATA3 expression, which weakens Treg function and can lead to inflammatory disease.
TSLP is used in macrophages, T cells, dendritic immune messenger cells, and innate lymphoid rapid-response immune cells. Both dendritic cells and innate lymphoid cells help bridge innate immunity, which is quick and nonspecific, and adaptive immunity, which is targeted and develops over time. TSLP is involved in signal transduction pathways that promote and inhibit inflammation, allergic responses, and immunity. It promotes type 2 inflammation caused by type 2 helper T cells, also known as Th2 cells. This activity is related to defense against parasites, but is also linked to allergic diseases. Interestingly, TSLP can inhibit type 1 inflammation to increase type 2 inflammation.
TSLP also influences Treg expansion through dendritic cells. In the skin, when vitamin D receptor (VDR) is activated in keratinocytes, TSLP production increases. TSLP produced by keratinocytes acts on dendritic cells, which migrate to skin-draining lymph nodes (filter lymph fluid coming from the skin) where they promote expansion (increasing activity and cell count) of Tregs to reduce inflammation. This expansion is caused by division of existing Tregs, rather than from naive T cells or from production in the thymus., TSLP, although important for inflammation regulation, can induce autoimmune disease. In atopic dermatitis, TSLP promotes inflammatory signaling pathways that increase production of IL-17A from TH17 cells. IL-17 is a pro-inflammatory cytokine that promotes mast (first responder) cell production, leading to skin lesions. Blocking TSLP reduces the production of IL-17A and improves inflammation, exemplifying TSLP’s role in inflammation.
One of the key groups of cells in the skin are dendritic cells (DCs), which act as antigen-presenting cells that pick up antigens from pathogens or damaged tissue and show them to T cells. Overall, they help guide how the immune system responds to issues. A specialized type of DC called Langerhans cells lives in the outer layer of the skin (the epidermis) and plays an important role in keeping the immune system balanced. These cells can interact directly with regulatory T cells (Tregs) using MHC class II molecules and co-stimulatory signals like CD80 and CD86, which helps Tregs grow and prevents too much immune activation . There are also other types of dendritic cells, like vitamin D3-responsive CD141⁺ DCs, that can specifically expand Tregs and reduce inflammation, showing how important the communication between DCs and Tregs is for keeping the skin’s immune system under control.
Furthermore, potential treatments to prevent TSLP induced inflammation have arisen. Due to TSLP’s role in the immune system, it has been targeted by medicines that work to treat autoimmune disorders. Recent research has shown that the hormone ghrelin can reduce inflammation in atopic dermatitis by directly suppressing TSLP production in skin cells. Topical treatment with ghrelin activates its receptor, GHSR1a, in keratinocytes, which leads to downstream activation of the glucocorticoid receptor (GR). This signaling pathway inhibits transcription of the TSLP gene. In addition, ghrelin activates protein kinase C (PKC), which phosphorylates the transcriptional coactivator p300, further decreasing TSLP promoter activity. Since TSLP acts as a major upstream driver of type 2 inflammatory responses in atopic dermatitis, its suppression results in reduced immune cell migration into the skin and less thickening of the outer skin layer. Overall, ghrelin helps reduce inflammation in the skin by blocking TSLP-related signaling pathways and calming allergic immune responses. Alternatively, Tezepelumab is an antibody that blocks TSLP signaling by preventing it from binding to its receptor. Studies have shown that tezepelumab has reduced asthma exacerbations, improves lung function, and decreases inflammatory biomarkers in wide ranges of patients. It is effective in cases with both low and high levels of eosinophils, white blood cells that intervene in allergic reactions and parasitic infections, and targets an upstream pathway.
Methods:
This experiment focuses on how a vitamin D3 analog, MC903, influences immune regulation in the skin by increasing TSLP production. It investigates how TSLP activates specific dendritic cell subsets to expand Tregs and help control immune responses. This study will use many mouse models, including wild-type mice, global TSLPR knockout mice, and mice without TSLPR specifically in dendritic cells. To trigger TSLP production in the skin, researchers will topically apply the vitamin D3 analog MC903 to both ears of mice once a day for five days, while control mice will receive ethanol instead. In previous studies, mice were sacrificed on day seven, and ear skin, skin-draining lymph nodes, mesenteric lymph nodes, and the spleen were collected. Flow cytometry, a process that identifies cell type/size and protein presence, is used to measure the total number of Foxp3+ Tregs in each tissue, which results from the production of TSLP. It will also be used to analyze dendritic cell populations, separating them into migratory and resident subsets. These cells will be identified as cDC1, cDC2, and double negative dendritic cells. Researchers have also performed DC-Treg co-culture assays in the past to test whether dendritic cells from MC903-treated mice increased Treg proliferation. Blocking assays will be used to figure out if co-stimulatory signaling was used.
Expected Results - How does TSLP activate dendritic cells to promote the expansion and function of regulatory T cells during immune responses?
It is expected that treatment with the vitamin D3 analog MC903 will increase TSLP production in the skin and lead to higher numbers of Foxp3+ tregs in skin-draining lymph nodes and the spleen. Migratory dendritic cells, especially cDC2s and double-negative dendritic cells, are expected to become more active and will show more expression of molecules such as CD80, CD86, and OX40L. Blocking these costimulatory molecules will be expected to reduce Treg expansion, which supports the idea that TSLP promotes immune system regulation by activating dendritic cells and utilizing co-stimulatory signaling pathways.



Comments